These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21384133)

  • 1. Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria.
    Rabbani N; Adaikalakoteswari A; Rossing K; Rossing P; Tarnow L; Parving HH; Thornalley PJ
    Amino Acids; 2012 May; 42(5):1627-39. PubMed ID: 21384133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
    Engelen L; Persson F; Ferreira I; Rossing P; Hovind P; Teerlink T; Stehouwer CD; Parving HH; Schalkwijk CG
    Nephrol Dial Transplant; 2011 Nov; 26(11):3573-7. PubMed ID: 21385863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
    Rossing K; Schjoedt KJ; Jensen BR; Boomsma F; Parving HH
    Kidney Int; 2005 Sep; 68(3):1190-8. PubMed ID: 16105050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.
    Palmer AJ; Roze S; Valentine WJ; Ray JA; Frei A; Burnier M; Hess B; Spinas GA; Brändle M
    Swiss Med Wkly; 2006 May; 136(21-22):346-52. PubMed ID: 16779715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
    Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
    Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
    Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
    Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
    Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
    Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced glycation endproducts, dityrosine and arginine transporter dysfunction in autism - a source of biomarkers for clinical diagnosis.
    Anwar A; Abruzzo PM; Pasha S; Rajpoot K; Bolotta A; Ghezzo A; Marini M; Posar A; Visconti P; Thornalley PJ; Rabbani N
    Mol Autism; 2018; 9():3. PubMed ID: 29479405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study.
    Piazza M; Hanssen NMJ; Persson F; Scheijen JL; van de Waarenburg MPH; van Greevenbroek MMJ; Rossing P; Hovind P; Stehouwer CDA; Parving HH; Schalkwijk CG
    Diabet Med; 2021 Sep; 38(9):e14405. PubMed ID: 32961617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Aug; 147(31-32):43. PubMed ID: 16128197
    [No Abstract]   [Full Text] [Related]  

  • 16. Modulation of advanced glycation end products by candesartan in patients with diabetic kidney disease--a dose-response relationship study.
    Saha SA; LaSalle BK; Clifton GD; Short RA; Tuttle KR
    Am J Ther; 2010; 17(6):553-8. PubMed ID: 19829095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes.
    Cetinkalp SS; Karadeniz MM; Erdogan MA; Ozgen GA; Yilmaz CO
    Saudi Med J; 2008 Oct; 29(10):1414-8. PubMed ID: 18946564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of oxidized and glycated proteins in clinical samples using mass spectrometry--a user's perspective.
    Thornalley PJ; Rabbani N
    Biochim Biophys Acta; 2014 Feb; 1840(2):818-29. PubMed ID: 23558060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy.
    Chen Y; Liu P; Chen X; Li Y; Zhang F; Wang Y
    Am J Med Sci; 2018 May; 355(5):418-424. PubMed ID: 29753370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.
    Andersen S; Mischak H; Zürbig P; Parving HH; Rossing P
    BMC Nephrol; 2010 Nov; 11():29. PubMed ID: 21040538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.